Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C62H86N12O16 |
Molecular Weight | 1255.4194 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CCCN1C(=O)[C@H](NC(=O)[C@@H](NC(=O)C3=C4N=C5C(OC4=C(C)C=C3)=C(C)C(=O)C(N)=C5C(=O)N[C@H]6[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@]7([H])CCCN7C(=O)[C@H](NC6=O)C(C)C)[C@@H](C)OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C2=O)C(C)C
InChI
InChIKey=RJURFGZVJUQBHK-IIXSONLDSA-N
InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
Molecular Formula | C62H86N12O16 |
Molecular Weight | 1255.4194 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 10 / 10 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1734954
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/1734954
Dactinomycin (actinomycin D) was isolated from Streptomyces by Selman Waksman in 1940s. The antibiotic shows anti-cancer activity; it was approved by FDA for the treatment of different cancer conditions among which are Ewing's sarcoma, Wilm's tumor, gestational trophoblastic disease, etc. Dactinomycin exerts its action by binding to DNA (preferably to GC motif) and thus inhibiting transcription.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2311221 |
156.25 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Primary | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Palliative | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Palliative | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
|||
Palliative | COSMEGEN Approved UseCOSMEGEN, as part of a combination chemotherapy and/or multi-modality treatment regimen, is indicated for the treatment of Wilms’ tumor, childhood rhabdomyosarcoma, Ewing’s sarcoma and metastatic, nonseminomatous testicular cancer. COSMEGEN is indicated as a single agent, or as part of a combination chemotherapy regimen, for the treatment of gestational trophoblastic neoplasia. COSMEGEN, as a component of regional perfusion, is indicated for the palliative and/or adjunctive treatment of locally recurrent or locoregional solid malignancies. Launch Date1964 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30.3 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253 |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
35.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931/ |
1.5 mg/m² 1 times / day steady-state, intravenous dose: 1.5 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: UNHEALTHY age: sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
142.4 mg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253 |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.62 mg × min/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931/ |
1.5 mg/m² 1 times / day steady-state, intravenous dose: 1.5 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: UNHEALTHY age: sex: FEMALE / MALE food status: UNKNOWN |
|
12.8 mg × min/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24968986/ |
1.5 mg/m² 1 times / day multiple, intravenous dose: 1.5 mg/m² route of administration: Intravenous experiment type: MULTIPLE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: UNHEALTHY age: CHILD sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253 |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
28.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16115931/ |
1.5 mg/m² 1 times / day steady-state, intravenous dose: 1.5 mg/m² route of administration: Intravenous experiment type: STEADY-STATE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: UNHEALTHY age: sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1667253 |
3 mg/kg single, intravenous dose: 3 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
DACTINOMYCIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months |
Other AEs: Pancytopenia, Mucositis... Other AEs: Pancytopenia (1 patient) Sources: Mucositis (severe, 1 patient) Pancreatitis (1 patient) Hyponatremia (1 patient) Hypocalcemia (1 patient) Respiratory distress (1 patient) Melena (1 patient) |
0.15 ug/kg multiple, intravenous Highest studied dose Dose: 0.15 ug/kg Route: intravenous Route: multiple Dose: 0.15 ug/kg Sources: |
unhealthy, 40-77 years Health Status: unhealthy Age Group: 40-77 years Sex: F Sources: |
|
1.5 mg/m2 single, intravenous Highest studied dose Dose: 1.5 mg/m2 Route: intravenous Route: single Dose: 1.5 mg/m2 Sources: |
unknown, children |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypocalcemia | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months |
Hyponatremia | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months |
Melena | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months |
Pancreatitis | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months |
Pancytopenia | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months |
Respiratory distress | 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months |
Mucositis | severe, 1 patient | 0.15 mg/kg 1 times / day multiple, intravenous Overdose Dose: 0.15 mg/kg, 1 times / day Route: intravenous Route: multiple Dose: 0.15 mg/kg, 1 times / day Sources: |
unhealthy, 18 months |
PubMed
Title | Date | PubMed |
---|---|---|
Polysaccharide Krestin enhances manganese superoxide dismutase activity and mRNA expression in mouse peritoneal macrophages. | 2000 |
|
Actinomycin D and staurosporine, potent apoptosis inducers in vitro, are potentially effective chemotherapeutic agents against glioblastoma multiforme. | 2000 |
|
VEGF expression in an osteoblast-like cell line is regulated by a hypoxia response mechanism. | 2000 Apr |
|
Testin induction: the role of cyclic 3',5'-adenosine monophosphate/protein kinase A signaling in the regulation of basal and lonidamine-induced testin expression by rat sertoli cells. | 2000 Dec |
|
Purinergic and adrenergic agonists synergize in stimulating vasopressin and oxytocin release. | 2000 Dec 1 |
|
Mechanisms of GM-CSF increase by diesel exhaust particles in human airway epithelial cells. | 2000 Jan |
|
Carcinogenic nickel induces genes involved with hypoxic stress. | 2000 Jan 1 |
|
Mimosine arrests cells in G1 by enhancing the levels of p27(Kip1). | 2000 Jan 10 |
|
Actinomycin D induces apoptosis and inhibits growth of pancreatic cancer cells. | 2000 May 1 |
|
Experimental model of hepatic venoocclusive disease (VOD) caused by dactinomycin--preliminary report about hepatoprotective effect of amifostine. | 2000 May-Jun |
|
Venoocclusive liver disease (VOD) as a complication of Wilms' tumour management in the series of consecutive 206 patients. | 2000 Oct |
|
Transient posterior encephalopathy induced by chemotherapy in children. | 2001 Feb |
|
Polyphyenolics increase t-PA and u-PA gene transcription in cultured human endothelial cells. | 2001 Feb |
|
Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells. | 2001 Feb |
|
The effects of particulate wear debris, cytokines, and growth factors on the functions of MG-63 osteoblasts. | 2001 Feb |
|
Differential induction of stearoyl-CoA desaturase and acyl-CoA oxidase genes by fibrates in HepG2 cells. | 2001 Feb 1 |
|
In vivo regulation of syndecan-3 expression in the rat uterus by 17 beta-estradiol. | 2001 Jan 5 |
|
Differential induction of rat hepatic cytochromes P450 3A1, 3A2, 2B1, 2B2, and 2E1 in response to pyridine treatment. | 2001 Mar |
|
Oxidant stress induces gamma-glutamylcysteine synthetase and glutathione synthesis in human bronchial epithelial NCI-H292 cells. | 2002 Apr |
|
Effect of actinomycin D on simian rotavirus (SA11) replication in cell culture. | 2002 Apr |
|
Pathways of induction of peroxiredoxin I expression in osteoblasts: roles of p38 mitogen-activated protein kinase and protein kinase C. | 2002 Apr 5 |
|
Induction and superinduction of 2,3,7,8-tetrachlorodibenzo-rho-dioxin-inducible poly(ADP-ribose) polymerase: role of the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator transcription activation domains and a labile transcription repressor. | 2002 Aug 15 |
|
Phospholipase D activation by sphingosine 1-phosphate regulates interleukin-8 secretion in human bronchial epithelial cells. | 2002 Aug 16 |
|
Interleukin 1beta induces functional prostaglandin E synthase in cultured human umbilical vein endothelial cells. | 2002 Dec |
|
Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance. | 2002 Dec 1 |
|
Changes in gene expression linked to methamphetamine-induced dopaminergic neurotoxicity. | 2002 Jan 1 |
|
Induction of MnSOD gene by arachidonic acid is mediated by reactive oxygen species and p38 MAPK signaling pathway in human HepG2 hepatoma cells. | 2002 Jun 1 |
|
Functional analysis of MRP1 cloned from bovine. | 2002 Jun 19 |
|
Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis. | 2002 May 17 |
|
Differential effects of thyroxine on metabolic enzymes and other macromolecules in a freshwater teleost. | 2003 Apr 1 |
|
Induction of 1-cys peroxiredoxin expression by oxidative stress in lung epithelial cells. | 2003 Aug |
|
An efficient, nonenzymatic method for isolation and culture of murine aortic endothelial cells and their response to inflammatory stimuli. | 2003 Jan-Feb |
|
Synergy between sulforaphane and selenium in the induction of thioredoxin reductase 1 requires both transcriptional and translational modulation. | 2003 Mar |
|
Differential expression of c-fos and c-myc protooncogenes by estrogens, xenobiotics and other growth-stimulatory agents in primary rat hepatocytes. | 2003 Mar |
|
Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor kappa B activation. | 2003 Mar 15 |
|
Leiomyosarcoma of urinary bladder following cyclophosphamide therapy: report of two cases. | 2003 May |
|
Leptin induces increased alpha2(I) collagen gene expression in cultured rat hepatic stellate cells. | 2003 May 15 |
|
Effects of hypoxia on monocyte inflammatory mediator production: Dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis. | 2003 Oct 3 |
|
Troglitazone inhibits cyclin D1 expression and cell cycling independently of PPARgamma in normal mouse skin keratinocytes. | 2004 Dec |
|
Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma. | 2004 Dec |
|
Overexpression of phospholipase D prevents actinomycin D-induced apoptosis through potentiation of phosphoinositide 3-kinase signalling pathways in Chinese-hamster ovary cells. | 2004 Mar 1 |
|
Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism. | 2004 Nov |
|
Coordinated secretion of alkaline phosphatase into serum and intestine in fat-fed rats. | 2004 Sep-Oct |
|
Establishment and characterization of new cellular lymphoma model expressing transgenic human MDR1. | 2005 Apr |
|
Mechanisms of thymidine kinase/ganciclovir and cytosine deaminase/ 5-fluorocytosine suicide gene therapy-induced cell death in glioma cells. | 2005 Feb 10 |
|
Induction of thioredoxin reductase as an adaptive response to acrolein in human umbilical vein endothelial cells. | 2005 Feb 25 |
|
Activation of peroxisome proliferator-activated receptor alpha increases the expression and activity of microsomal triglyceride transfer protein in the liver. | 2005 Jan 14 |
|
Mechanism of TNF-{alpha} modulation of Caco-2 intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. | 2005 Mar |
|
Mitochondrial redox state regulates transcription of the nuclear-encoded mitochondrial protein manganese superoxide dismutase: a proposed adaptive response to mitochondrial redox imbalance. | 2005 Mar 1 |
|
Promoting insulin secretion in pancreatic islets by means of bisphenol A and nonylphenol via intracellular estrogen receptors. | 2005 May |
Patents
Sample Use Guides
Wilms’ Tumor, Childhood Rhabdomyosarcoma and Ewing’s Sarcoma: Regimens of 15 mcg/kg intravenously daily for five days administered in various combinations and schedules with other chemotherapeutic agents; Metastatic Nonseminomatous Testicular Cancer: 1000 mcg/m2 intravenously on Day 1 as part of a combination regimen with cyclophosphamide, bleomycin, vinblastine, and cisplatin; Gestational Trophoblastic Neoplasia: 12 mcg/kg intravenously daily for five days as a single agent. 500 mcg intravenously on Days 1 and 2 as part of a combination regimen with etoposide, methotrexate, folinic acid, vincristine, cyclophosphamide and cisplatin; Regional Perfusion in Locally Recurrent and Locoregional Solid Malignancies: 50 mcg (0.05 mg) per kilogram of body weight for lower extremity or pelvis, 35 mcg (0.035 mg) per kilogram of body weight for upper extremity.
Route of Administration:
Intravenous
Human osteosarcoma cell line MG63 were incubated with dactinomycin (actinomycin D) at final concentrations of 0.1, 0.5, 1 and 5 uM during 0, 2, 6 and 24 hours. The drug was shown to inhibit the proliferation of cells by decreasing cyclin gene transcriptions.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Apr 02 07:33:17 GMT 2025
by
admin
on
Wed Apr 02 07:33:17 GMT 2025
|
Record UNII |
1CC1JFE158
|
Record Status |
FAILED
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C204
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
||
|
NDF-RT |
N0000000233
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
||
|
LIVERTOX |
NBK548778
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
||
|
IARC | Actinomycin D | ||
|
NDF-RT |
N0000000150
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
||
|
NDF-RT |
N0000180850
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
||
|
WHO-ATC |
L01DA01
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
||
|
WHO-VATC |
QL01DA01
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
1162400
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
3220
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
457193
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
DB00970
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
m4067
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | Merck Index | ||
|
Dactinomycin
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
SUB129914
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
50-76-0
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
1CC1JFE158
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
C412
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
200-063-6
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
DTXSID9020031
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
1CC1JFE158
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
DACTINOMYCIN
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | Description: An orange-red to red, crystalline powder.Solubility: Soluble in water at 10 ?C and slightly soluble in water at 37 ?C; freely soluble in ethanol (~750 g/l) TS and methanol R;very slightly soluble in ether R.Category: Cytotoxic drug.Storage: Dactinomycin should be kept in a tightly closed container, protected from light, and stored at a temperature notexceeding 40 ?C.Additional information: Dactinomycin is hygroscopic and is affected by light and heat.CAUTION: Dactinomycin must be handled with care, avoiding contact with the skin and inhalation of airborne particles. | ||
|
SUB13528MIG
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
27666
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
D003609
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
CHEMBL1554
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
100000085032
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
1155
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
3100
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | RxNorm | ||
|
Dactinomycin
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
774
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY | |||
|
3053
Created by
admin on Wed Apr 02 07:33:17 GMT 2025 , Edited by admin on Wed Apr 02 07:33:17 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||